RetaCalc
Protocol library
SingleInvestigationalPhase 2Low confidenceSourced

LL-37

A human antimicrobial peptide studied clinically as a topical wound product. Controlled evidence does not validate systemic or subcutaneous injection.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Adults with hard-to-heal venous leg ulcers

Topical 0.5 mg/mL or 1.6 mg/mL LL-37 applied twice weekly for 13 weeks

The phase 2b study combined topical study product with compression therapy; this is not an injectable protocol.

View source

Evidence summary

A human antimicrobial peptide studied clinically as a topical wound product. Controlled evidence does not validate systemic or subcutaneous injection.

Protocol basis

The strongest protocol is topical and wound-specific. The page preserves concentration, frequency and compression context but does not translate them to injection.

What remains uncertain

Systemic safety, subcutaneous pharmacokinetics and benefit outside topical wound care are not established.

Warnings and contraindications

The human trials applied LL-37 topically to venous leg ulcers.
Topical concentrations cannot be converted into systemic injection quantities.
The larger phase 2b trial did not improve healing in the full study population.